RedHill Could Soon Seek EUA For COVID-19 Therapy
Opaganib Shows Promise In Severe Sufferers
The Israel-based, NASDAQ-listed biotech tells Scrip that if the oral SK2 selective inhibitor succeeds in a Phase II/III study, it would be "very comfortable" taking opaganib all the way to market on its own.
